Home › Calculator › INKT Dividend Calculator 2026
INKT Dividend DRIP Calculator 2026
17.18% YieldHealthcareMiNK Therapeutics, Inc. · NASDAQ
Price: $11.64 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When INKT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your INKT snowball 📈
$10,000 in INKT → $48.8K in 10 years · $596.55/month
About MiNK Therapeutics, Inc. (INKT) — Dividend Analysis 2026
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Compare INKT with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full INKT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open INKT position with:
🌍 INKT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold INKT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 17.18% | 14.38% | $1,718 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 14.60% | 11.80% | $1,460 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 13.74% | 10.94% | $1,374 / yr |
| 🇬🇧 UK ISA | 0% | 17.18% | 14.38% | $1,718 / yr |
| 🇬🇧 UK Taxable | 8.75% | 15.68% | 12.88% | $1,568 / yr |
| 🇨🇦 TFSA | 0% | 17.18% | 14.38% | $1,718 / yr |
| 🇨🇦 CA Taxable | 25% | 12.88% | 10.09% | $1,289 / yr |
| 🇦🇺 Super (pension) | 15% | 14.60% | 11.80% | $1,460 / yr |
| 🇦🇺 AU Taxable | 30% | 12.03% | 9.23% | $1,203 / yr |
| 🇩🇪 DE Taxable | 26.375% | 12.65% | 9.85% | $1,265 / yr |
| 🇫🇷 FR Taxable | 30% | 12.03% | 9.23% | $1,203 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 INKT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 INKT Dividend Payment Schedule
INKT pays quarterly — 4 times per year. Next ex-div: TBD.
📊 INKT vs Healthcare Benchmarks
How INKT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for INKT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ INKT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-01 | 1,279 | $10.95 | $14.0K | ||
| A-Award | 2026-09-01 | 1,233 | $10.95 | $13.5K | ||
| A-Award | 2026-09-01 | 1,485 | $10.95 | $16.3K | ||
| A-Award | 2026-09-01 | 1,622 | $10.95 | $17.8K | ||
| A-Award | 2026-09-01 | 1,633 | $10.95 | $17.9K | ||
| Sale | 2026-06-04 | 500 | $12.68 | $6.3K | ||
| Sale | 2026-06-04 | 1,000 | $12.80 | $12.8K | ||
| A-Award | 2026-06-01 | 1,091 | $12.38 | $13.5K | ||
| A-Award | 2026-03-02 | 1,239 | $10.90 | $13.5K | ||
| A-Award | 2026-06-01 | 1,434 | $12.38 | $17.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the INKT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
MiNK Therapeutics, Inc. (INKT) is currently trading at $11.64, 94% below its 52-week high. The current dividend yield is 17.18% based on an annual payout of $2.00 per share.
INKT (MiNK Therapeutics, Inc.) — 17.18% Dividend Yield Analysis
MiNK Therapeutics, Inc. (INKT) is a healthcare stock currently trading at $11.64 with a dividend yield of 17.18%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (17.18%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.